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Farnesoid X Receptor Activation Protects 
Liver From Ischemia/Reperfusion Injury 
by Up-Regulating Small Heterodimer 
Partner in Kupffer Cells
Dan Jin,1,2 Tianfei Lu,3* Ming Ni,1* Han Wang,1 Jiang Zhang,3 Chenpeng Zhong,3 Chuan Shen,3 Jun Hao,3 Ronald W. Busuttil ,1 
Jerzy W. Kupiec-Weglinski,1 Jianjun Zhang,3 Ning Xu,3 and Yuan Zhai 1
Farnesoid X receptor (FXR) is the nuclear receptor of bile acids and is involved in innate immune regulation. FXR ag-
onists have been shown to protect multiple organs from inflammatory tissue injuries. Because liver expresses high levels 
of FXR, we explored the potential therapeutic benefits and underlying mechanisms of pharmacologic FXR activation 
in a murine model of partial liver warm ischemia. Pretreatment of mice with FXR agonist 3-(2,6-dichlorophenyl)-
4-(3′-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064) attenuated liver ischemia/reperfusion in-
juries (IRIs) in wild-type but not FXR knockout mice. Posttreatment with GW4064 facilitated liver recovery from 
IRI. Mechanistically, Kupffer cells (KCs) expressed much higher levels of FXR than bone marrow-derived macrophages 
(BMMs). Pretreatment of KCs but not BMMs with GW4064 resulted in lower tumor necrosis factor α but higher 
interleukin-10 expressions following toll-like receptor stimulation. FXR-targeted gene small heterodimer partner (SHP) 
was critical for the regulation of KC response by GW4064. In vivo, the depletion of KCs but not cluster of differen-
tiation (CD) 11b+ cells or knockdown of SHP diminished the immune regulatory effect of GW4064 in liver IRI. Thus, 
FXR activation protects liver from IRI by up-regulating SHP in KCs to inhibit the liver proinflammatory response. 
(Hepatology Communications 2020;4:540-554).
Ischemia/reperfusion injury (IRI) is a major com-plication in liver surgeries.(1) In liver transplanta-tion, despite the advances in surgical techniques 
and organ preservations, IRI remains responsible for 
approximately 10% of early graft failure(2) and leads 
to a higher incidence of acute and chronic rejection. 
These adverse effects may become more significant 
in liver transplants with expanded criteria, including 
those from marginal, deceased, and nonbeating-heart 
donors. Thus, development of an effective therapeutic 
strategy against liver IRI will help to not only improve 
the outcome of liver transplantation but also expand 
the donor pool to alleviate the severe organ shortage 
for liver transplantation.(3)
The pathophysiology of liver IRI is complicated. 
Hepatocellular damages result from at least two 
insults: primary cellular destruction due to metabolic/
oxidative stress and secondary cytotoxicity sequent 
Abbreviations: ASC, apoptosis-associated speck-like protein; B6 mice, C57BL/6J mice; BMM, bone marrow-derived macrophage; Bsep, bile salt 
export pump; CD, cluster of differentiation; CL, clodronate-encapsulated liposome; Ctl, control; Cyp7a1, cytochrome P450 family 7 subfamily A member 
1; DT, diphtheria toxin; DTR, DT receptor; FBS, fetal bovine serum; FXR, farnesoid X receptor; GW4064/GW, 3-(2,6-dichlorophenyl)-4-(3′-
carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole; HE, hematoxylin and eosin; HPRT, hypoxanthine-guanine phosphoribosyltransferase; 
IL, interleukin; iMՓ, inf iltrating macrophage; IR, ischemia/reperfusion; IRI, ischemia/reperfusion injury; KC, Kupffer cell; KD, knockdown; LPS, 
lipopolysaccharide; MФ, macrophage; NF-κB, nuclear factor kappa B; NLR, nucleotide-binding oligomerization domain-like receptor; NLRP3, NLR 
family pyrin domain containing 3; NPC, nonparenchymal cell; OCA, obeticholic acid; Ostβ, organic solute transporter beta; qRT-PCR, quantitative 
reverse-transcription polymerase chain reaction; sALT, serum alanine aminotransferase; SHP, small heterodimer partner; siRNA, small interfering 
RNA; ssiRNA, scrambled small interfering RNA; TGR5, Takeda G protein-coupled receptor 5; TLR, toll-like receptor; TNF-α, tumor necrosis factor 
alpha; WT, wild type.
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to tissue inflammation. Liver ischemia/reperfusion 
(IR) triggers an innate immune-dominated inflam-
matory response mediated by the sentinel pattern 
recognition receptor (PRR) system.(3,4) It has been 
documented that a danger-associated molecular pat-
tern (DAMP), such as high-mobility group box 1 
(HMGB-1), derived from necrotic/stressed cells(4-6) 
activates PRRs, including toll-like receptors (TLRs) 
and nucleotide-binding oligomerization domain-
like receptors (NLRs),(5-11) to initiate the response. 
Macrophages (MФs) are the major innate immune 
cells responding to DAMPs in liver IRI. Infiltration 
and activation of peripheral monocyte-derived 
infiltrating MՓs (iMՓs) is the cardinal feature of 
IR-induced inflammatory response. The liver is a 
unique organ in that it contains a large number of 
resident MΦs (Kupffer cells [KCs]) in the homeo-
static state. KCs represent approximately 35% of liver 
nonparenchymal cells (NPCs) and 80% to 90% of all 
tissue MΦs in the body.(12) Both KCs and iMՓs are 
involved in the pathogenesis of liver IRI.
Farnesoid X receptor (FXR) is the nuclear receptor 
for bile acids and a member of the nuclear hormone 
receptor family with transcriptional factor activities. 
It is highly expressed in liver, kidneys, and small 
intestine.(13) FXR binds to promoters of its  target 
genes in a ligand-dependent manner and regu-
lates transcriptions of genes involved in cholesterol/ 
bile acid metabolism, hepatic gluconeogenesis, and 
lipogenesis. FXR regulates hepatic fibrosis, nonalco-
holic fatty liver disease liver regeneration, and acute 
hepatitis.(14,15) In organ ischemia models, the roles of 
FXR have been controversial and seem to be organ 
specific. Pharmacologic inhibition or genetic ablation 
of FXR significantly reduced myocardial apopto-
sis, decreased infarct, and improved cardiac function 
in IR myocardium.(16) FXR activation by its ago-
nists, such as 3-(2,6-dichlorophenyl)-4-(3′-carboxy- 
2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxaz-
ole (GW4064) and 6α-ethyl-chenodeoxycholic acid 
(6α-ECDCA), protected small intestine and kid-
neys from IRI and attenuated local inflammatory 
responses.(17,18) In liver, obeticholic acid (OCA) mar-
ginally reduced IRI in a rat model.(19) In the cur-
rent study, we explored the therapeutic potential of 
pharmacologic FXR activation and the underlying 
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mechanism in the pathophysiology of liver IRI in a 
murine model of partial hepatic warm ischemia.
Materials and Methods
animals
Male C57BL/6J (B6) and FXR-deficient 
(Nr1h4tm1Gonz/J) mice (6-8  weeks old) were pur-
chased from the Jackson Laboratory (Bar Harbor, 
ME). All mice were housed in the University of 
California Los Angeles (UCLA) animal facil-
ity under a specific pathogen-free condition and 
received humane care according to the crite-
ria outlined in the Guide for the Care and Use 
of Laboratory Animals prepared by the National 
Academy of Sciences and published by the National 
Institutes of Health. All animal experiments were 
approved by the UCLA Office of the Animal 
Research Oversight Committee.
liVeR iRi moDel
After a midline laparotomy, mice were injected 
with heparin (100 μg/kg), and an atraumatic clip was 
used to interrupt arterial/portal venous blood supply 
to the cephalad liver lobes. After 60 to 90 minutes of 
ischemia, the clip was removed to initiate liver reper-
fusion. Sham controls underwent the same proce-
dure but without vascular occlusion. Mice were killed 
after 6  hours or 5  days of reperfusion, and liver and 
serum samples were collected. To test the effect on 
acute liver IRI, GW4064 (5 mg/kg, intraperitoneally; 
Tocris Bioscience) or OCA (30  mg/kg, oral gavage; 
Sigma-Aldrich, St Louis, MO) was administered 1 to 
2 hours before the onset of liver ischemia. To test the 
effect on liver recovery from IRI, GW4064 (5 mg/kg) 
was administered intraperitoneally at 24 hours, day 2, 
day 3, and day 4 after reperfusion. Levels of serum 
alanine aminotransferase (sALT) were measured with 
an autoanalyzer by IDEXX Laboratories (Westbrook, 
Maine). A portion of the liver specimens was fixed 
in 10% buffered formalin and embedded in paraffin. 
Liver sections (4 μm) were stained with hematoxylin 
and eosin (HE). The severity of liver IRI was graded 
blindly using Suzuki’s criteria(20) on a scale from 0 to 4. 
Liver sections were processed for immunohistochemi-
cal staining of myeloperoxidase (Novus Biologicals) to 
quantitate polymorphonuclear leukocyte infiltration 
as described.(21,22)
IN VIVO Depletion oF KCs anD 
ClusteR oF DiFFeRentiation 
11B+ mФs
KCs were depleted using the Macrophage Depletion 
Kit (Encapsula NanoSciences, LLC, Brentwood, TN). 
In brief, 200 μL/mouse of clodronate-encapsulated 
liposomes (CLs) or control liposomes was injected 
in B6 mice intravenously 48  hours before the onset 
of liver ischemia. In cluster of differentiation (CD) 
11b-diphtheria toxin (DT) receptor (DTR) mice, 
10  μg/g DT was injected intravenously 48  hours 
before the onset of liver ischemia. The depletion 
of KCs or CD11b MФs was confirmed by fluores-
cence-activated cell sorting (FACS) analysis of liver 
NPCs 6 hours after reperfusion. CL treatment effec-
tively depleted KCs but spared iMՓs; DT treatment 
depleted CD11b cells (both iMՓs and neutrophils) 
but spared KCs in CD11b-DTR mice (Supporting 
Fig. S1A). Furthermore, immunofluorescence staining 
of liver sections with anti-F4/80-fluorescein isothio-
cyanate and 4′,6-diamidino-2-phenylindole revealed 
the depletion of KCs by CL treatment (Supporting 
Fig. S1B).
QuantitatiVe ReVeRse-
tRansCRiption polymeRase 
CHain ReaCtion
Total RNA (2.0 μg) was reverse transcribed into 
complementary DNA (cDNA) using Oligo (dT) 
12-18 Primer and M-MLV Reverse Transcriptase 
kit (Invitrogen, Carlsbad, CA). Quantitative 
reverse-transcription polymerase chain reaction 
(qRT-PCR) was performed using the QuantStudio 
3 System (Thermo Fisher Scientific, Waltham, MA). 
In a final reaction volume of 20 µL, we mixed 1× PCR 
Mix (Power SYBR Green PCR Master Mix; Life 
Technologies, Woolston, United Kingdom), cDNA, 
and 0.125  μM of each primer. The amplification 
condition was 50°C/2  minutes, 95°C/10  minutes, 
followed by 40 cycles of 95°C/15  seconds, 
60°C/1 minute. Primers for Fxr and its target genes 
are listed in Table 1. Other primers used to amplify 
specific mouse gene fragments are the same as 
described.(23)
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KC isolation
Liver NPCs were isolated from normal or IR 
 livers of B6 mice by in situ collagenase perfusion. In 
brief, livers were perfused through the portal vein 
with calcium- and magnesium-free Hank’s balanced 
salt solution (HBSS) supplemented with 2% heat- 
inactivated fetal bovine serum (FBS), followed by 
0.27% collagenase IV (Sigma-Aldrich). Perfused liv-
ers were dissected and filtered through 70-μm nylon 
mesh cell strainers (BD Biosciences, San Diego, CA). 
NPCs were separated from hepatocytes by low-speed 
centrifugation (50g, 2  minutes) 3 times. NPCs were 
stained with fluorescence-labeled antibodies and 
analyzed by FACS. To enrich KCs, NPCs were sus-
pended in HBSS and layered onto a two-layer 25% 
to 50% Percoll gradient (Sigma-Aldrich) in a 50-mL 
conical centrifuge tube and centrifuged at 1,800g at 
4°C for 15 minutes. KCs in the middle layer were col-
lected and allowed to attach to cell-culture plates in 
supplemented Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% FBS for 15  minutes at 37°C. 
Nonadherent cells were removed by replacing the cul-
ture medium. The purity of KCs in the adherent cells 
was approximately 80%, as determined by immunoflu-
orescent staining with anti-F4/80.
Bone maRRoW-DeRiVeD 
maCRopHages
Bone marrow cells were isolated from mouse 
femurs and tibias. Cells were cultured in DMEM sup-
plemented with 10% FBS and 20% L929-conditioned 
medium for 7  days. Bone marrow-derived macro-
phages (BMMs) were then replated and cultured over-
night in new culture dishes for further experiments.
WesteRn Blot analysis
Cellular proteins were extracted with ice-cold lysis 
buffer (1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate [SDS], 10% glycerol, 
137 mM sodium chloride, 20 mM Tris, pH 7.4). Proteins 
(20 μg) were subjected to 12% SDS-polyacrylamide gel 
electrophoresis and transferred to a polyvinylidene fluo-
ride nitrocellulose membrane. Antibodies against FXR 
(D-3, SC25309) and β-actin (Santa Cruz Technology) 
were used to probe the membrane.
small HeteRoDimeR paRtneR 
KnoCKDoWn
Small heterodimer partner (SHP) small interfering 
RNA (siRNA) with a pool of three target-specific siR-
NAs (sc-44870; Santa Cruz Biotechnology) was used 
to knock down SHP gene expression. In vitro, BMMs 
were transiently transfected with siRNA using LipoJet 
In Vitro Transfection Kit (SignaGen Laboratories) 
according to the manufacturer’s protocol. In vivo, siR-
NAs were mixed with mannose-conjugated polymers 
(Polyplus-transfection SA) at a ratio specified by the 
manufacturer and administered intraperitoneally (siRNA 
2 mg/kg) 3 hours before the onset of liver ischemia.
IN VITRO mФ aCtiVation
KCs (control or SHP siRNA transfected) or BMMs 
were stimulated with lipopolysaccharide (LPS) (100-
500 ng/mL; InvivoGen, San Diego, CA) in the absence 
or presence of GW4064 (10  μM; Tocris), or OCA 
(10  μM; MedChemExpress), or INT-777 (3  μM; 
Cayman Chemical). Culture supernatants were col-
lected at 0, 6, and 24 hours after stimulation for cyto-
kine measurements. Cells were collected at 3 to 6 hours 
after stimulation for RNA/protein preparation.
statistiCs
Results are shown as mean  ±  SD. Comparisons 
between two parameters were analyzed by the 
unpaired Student t test. Multiple group comparisons 
were performed using one-way analysis of variance 
followed by Bonferroni’s post hoc test. All analyses 
were performed using Stata software (version 11.0). 
P < 0.05 (two-tailed) was considered statistically 
significant.
taBle 1. pRimeRs FoR qRt-pCR
Gene 5′ Primer 3′ Primer
Fxr GGGATGAGCTGTGTGTTGTC GGCGTTCTTGGTAATGCTTC
Abcb4 AATTGGCCTGTTGACACTGTT GGAAGACCTGATCCATGAGC
Shp CTCTGCAGGTCGTCCGACTATTCTG CCTCGAAGGTCACAGCATCCTG
Ostβ AGCCTGAAGTCCCAGGAATC TGCACTGTGGTCCATGTTTC
Bsep GGACACACCTGAGAGGACCTT AGATCGTTGACGGATGGAAG
Cyp7a1 TCAAGCAAACACCATTCCTG GGCTGCTTTCATTGCTTCA
Abbreviation: Abcb4, adenosine triphosphate binding cassette sub-
family B member 4.
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Results
FXR pHaRmaCologiC 
aCtiVation pRoteCts liVeR 
FRom iRi
To test whether pharmacologic activation of FXR 
protected livers from IRI, the selective FXR agonist 
GW4064 was administered in wild-type (WT) B6 
mice before the onset of liver ischemia (90 minutes). 
Liver FXR activation by GW4064 in vivo was con-
firmed by qRT-PCR analysis of FXR target gene 
expressions, including up-regulation of organic solute 
transporter beta (Ostβ), bile salt export pump (Bsep), 
and Shp and the down-regulation of cytochrome P450 
family 7 subfamily A member 1 (Cyp7a1) in sham livers 
of WT mice (Fig. 1A). IR inhibited liver FXR expres-
sion and its activities, as evidenced by the lower lev-
els of expressions of FXR proteins and FXR-targeted 
genes in IR livers than those in shams (Fig. 1A,B). 
However, FXR activation remained able to up-regulate 
its targeted genes in IR livers as their expression levels 
were higher in GW4064-treated livers than those in 
controls at 6  hours after reperfusion. Functionally, 
GW4064 treatment resulted in a significant protec-
tion of livers from IRI. There were lower levels of 
sALT and better preserved liver histologic architec-
tures with improved Suzuki scores in the GW4064-
treated versus vehicle-treated cohorts (Fig. 1C). 
The therapeutic benefit of FXR activation in liver 
IRI was confirmed with a second FXR agonist, 
OCA (INT-747), under a milder ischemic condition 
(60  minutes of ischemia; Supporting Fig. S2). Liver 
inflammatory immune activation was also inhibited 
by GW4064, as indicated by lower levels of tumor 
necrosis factor α (TNF-α), interleukin-1β (IL-1β), 
and IL-6 expressions in IR livers (Fig. 1D). The liver- 
protective effects of GW4064 were absent in FXR 
knockout (KO) hosts (Supporting Fig. S3), confirm-
ing the target specificity of the pharmacologic agent 
in vivo.
To further explore the therapeutic potential of 
pharmacologic activation of FXR in liver IRI, we 
determined whether postischemia treatment could 
Fig. 1. FXR activation protects livers from IRI. B6 mice pretreated with or without (control) FXR agonist GW4064 were subjected to 
90 minutes of partial liver warm ischemia followed by 6 hours of reperfusion, as described in Materials and Methods. (A) Plots of average 
FXR target gene/HPRT ratios in livers of different experimental groups. Gene expressions in liver tissues were measured by qRT-PCR. 
(B) Western blotting of FXR and SHP in liver tissues. (C) Representative liver HE staining (magnification ×100), plots of average sALT 
levels, and liver Suzuki scores of different experimental groups. (D) Plots of average inflammatory gene/HPRT ratios in livers. Data 
represent Mean ± SD, n = 4-6/group; *P < 0.05. Abbreviations: h, hour; NS, not significant.
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improve liver recovery from IRI. In our model of 
liver IRI, it usually takes liver 7 days to recover from 
90 minutes warm ischemia-induced liver reperfusion 
injury (data not shown). GW4064 was administered 
daily starting at 24  hours after reperfusion. Liver 
recovery from IRI was evaluated at day 5 after reper-
fusion when the repair of hepatocellular damage was 
incomplete in IR livers of controls. Posttreatment 
with GW4064 facilitated  liver recovery from IRI 
such that liver histologic damage in these treated 
mice was nearly all repaired at this time point, with 
significantly lower Suzuki scores compared with 
those in controls (Fig. 2A). The sALT levels were all 
at baseline at this time point of reperfusion in both 
groups of mice (data not shown). At the molecular 
level, GW4064 treatment resulted in lower TNF-α 
levels but higher levels of gene expressions related 
to reparative MФs, such as Mer tyrosine kinase 
(MerTK) and T-cell immunoglobulin mucin pro-
tein 4 (TIM-4) (Fig. 2B). The activation of FXR in 
IR livers by GW4064 was confirmed by qRT-PCR 
analysis of FXR target gene expressions (Fig. 2C). 
Thus, FXR pharmacologic activation protects liver 
from IRI. The pretreatment regimen reduces hepa-
tocellular damage and inhibits liver inflammatory 
response against IR, and the postischemic regimen 
facilitates liver recovery from IRI.
DiFFeRential Regulation 
oF KCs anD Bmms By FXR 
aCtiVation
FXR is expressed in both parenchymal cells and 
NPCs in the liver. FXR activation-induced liver pro-
tection could potentially result from direct cytoprotec-
tion in hepatocytes or immune regulation by immune 
Fig. 2. FXR activation facilitates liver recovery from IRI. B6 mice were subjected to 90 minutes of partial liver warm ischemia and 
divided into two groups treated with daily injection of either the vehicle control or GW4064, as described in Materials and Methods. 
IR liver tissues were harvested at day 5 after reperfusion. (A) Representative liver HE sections (magnification ×100) and plots of average 
Suzuki scores of control and GW groups. (B,C) Plots of average target gene/HPRT ratios of different experimental groups. Inflammatory 
and FXR-targeted gene expressions in sham and IR livers were measured by qRT-PCR. Representative results of two independent 
experiments; Data represent Mean ± SD, n = 4-6/group; *P < 0.05, **P < 0.01. Abbreviations: d, day; MerTK, Mer tyrosine kinase; TIM-4, 
T-cell immunoglobulin mucin protein 4.
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cells. Because FXR activation has been shown to regu-
late hepatocyte proliferation and immune response, we 
focused on whether liver-resident KCs were involved 
in the protection of liver from IRI. We first analyzed 
FXR expression in liver tissues and KCs/NPCs at 
resting state and during IRI as well as in BMMs in 
response to LPS. Liver tissues expressed the highest 
level of FXR. KCs/NPCs also expressed the receptor 
gene, whereas BMMs expressed it at minimal levels, 
which was nearly 1,000-fold lower compared with 
KCs (Fig. 3A). IR down-regulated FXR expression 
in liver and NPCs, and LPS stimulation up-regulated 
FXR in BMMs. At the protein level, western blot 
analysis showed that KCs but not BMMs expressed 
FXR, which was increased by GW4064 treatment and 
decreased by LPS stimulation (Fig. 3B).
Because FXR was differentially expressed in KCs 
and BMMs, we next determined whether pharmaco-
logic FXR activation regulated these MФs differently 
in their inflammatory activation in vitro. Preincubation 
with 10  μM GW4064 for 2  hours resulted in Shp 
up-regulation in both resting and LPS-stimulated KCs 
but not in BMMs, indicative of functional FXR in 
KCs but not BMMs (Fig. 3C). Interestingly, although 
Fig. 3. FXR expressions and functions in macrophages. (A) Plots of average FXR/HPRT gene expression ratios in livers and macrophages. 
FXR expressions were determined by qRT-PCR in sham or IR livers (6 hours after reperfusion), liver NPCs (isolated from sham or IR 
livers after 0 or 6 hours of reperfusion), or BMMs stimulated with LPS for 0 and 6 hours in vitro. (B) Western blots of FXR expressions 
in KCs and BMMs. (C, D) Plots of target gene/HPRT ratios in KCs and BMMs. KCs were isolated from sham livers, and BMMs were 
derived from 7-day cultures of bone marrow cells, as described in Materials and Methods. These macrophages were pretreated with either 
vehicle controls or GW4064 followed by 3 hours of stimulation of LPS. Gene expressions were determined by qRT-PCR. Representative 
results of at least two independent experiments; Data represent Mean ± SD, n = 3-6/group; *P < 0.05. Abbreviations: DMSO, dimethyl 
sulfoxide; PBS, phosphate-buffered saline.
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LPS down-regulated Shp in control BMMs, the SHP 
level was sustained in GW4064-treated BMMs. FXR 
gene expression was increased by GW4064 treat-
ment in KCs and BMMs. LPS stimulation decreased 
FXR in KCs but increased it in BMMs. FXR acti-
vation inhibited KC proinflammatory activation by 
decreased TNF-α (~50%) but increased IL-10 (~30%) 
gene expression following LPS stimulation (Fig. 3C). 
In BMMs, however, GW4064 only marginally inhib-
ited LPS-induced TNF-α expression (~10%) without 
significant impact on IL-10 (Fig. 3D). These results 
demonstrate distinctive expression patterns and regu-
latory effects of FXR in KCs and BMMs.
We also tested the potential immune regula-
tory effect of the FXR agonist OCA (INT-747) 
and Takeda G protein-coupled receptor 5 (TGR5) 
agonist INT-777 on KCs and BMMs in vitro 
(Supporting Fig. S4). Similar to GW4064, OCA 
selectively modulated KCs but not BMMs in 
response to LPS stimulation. Importantly, OCA 
increased Shp expression in KCs in both resting 
and activation states. Interestingly, TGR5 activa-
tion by INT-777 regulated both KCs and BMMs in 
response to LPS such that the expression of TNF-α 
was decreased with simultaneous increases of IL-10. 
However, INT-777 failed to induce Shp expression 
in KCs. These results indicate that FXR activation 
selectively targets KCs whereas TGR5 activation 
affects both KCs and BMMs in their inflammatory 
response and that Shp is an FXR- but not a TGR5-
inducible gene.
KCs But not Bmms aRe 
CRitiCal FoR FXR-meDiateD 
pRoteCtion in liVeR iRi
To test whether KCs mediated FXR activation- 
induced liver protection against IRI, KCs were depleted 
by CLs and administered intravenously 48  hours 
before the onset of liver ischemia. Liver inflammation 
and injury were evaluated at 6 hours after reperfusion. 
Consistent with previous studies,(24-26) CL-mediated 
KC depletion resulted in increases in liver IRI, with 
higher levels of sALT and more severely damaged liver 
histologic architectures in CL-treated versus blank 
liposome-treated mice (Fig. 4A). Interestingly, FXR 
activation by GW4064 was no longer able to protect 
liver from IRI in KC-depleted mice because there were 
no differences in sALT levels or liver histopathology 
between GW4064-treated and vehicle-treated cohorts 
(Fig. 4A). FXR activation also failed to inhibit liver 
inflammatory gene induction by IR, including TNF-α, 
IL-1β, and IL-6, in the absence of KCs (Fig. 4B). It 
was noted that the GW4064-induced alterations of 
FXR-targeted genes in liver were diminished by CL 
treatment, indicating that KCs were responsive to 
FXR activation in vivo (Fig. 4C). These results indi-
cate that KCs are required for FXR-mediated inhibi-
tion of liver proinflammatory response and protection 
of liver from IRI. To address the possibility that the 
KC-depleted livers were damaged too much to res-
cue by FXR activation, we repeated the experiment 
under a milder ischemia condition (60 minutes). Liver 
IRI at 6 hours after reperfusion was significantly less 
after 60 minutes of ischemia compared with that after 
90  minutes of ischemia (Supporting Fig. S2), sALT 
levels were lower, and liver parenchymal damage was 
less severe. Under the 60-minute ischemia condition, 
KC depletion resulted in higher liver IRI, comparable 
to that in control livers after 90 minutes of ischemia. 
Pretreatment with OCA was not able to protect those 
KC-depleted livers from IRI, confirming the role of 
KCs in mediating the liver-protective effect of FXR 
activation.
Next, we tested whether iMՓs, derived from 
bone marrow, were also involved in FXR activation- 
induced liver protection. DT was used to deplete 
CD11b+  BMMs in CD11b-DTR mice 48  hours 
before the onset of liver ischemia. CD11b-depleted 
mice developed less severe liver IRI compared 
with controls. Interestingly, GW4064 treatment 
remained effective in ameliorating liver injury in 
these CD11b-depleted cohorts, with sALT levels 
reduced, liver histologic architectures better pre-
served, and lower Suzuki scores (Fig. 5A). FXR acti-
vation remained inhibitory to the liver inflammatory 
response against IR in the absence of CD11b 
BMMs. Levels of TNF-α, IL-6, and IL-1β were 
lower and IL-10 was higher in IR livers treated 
with GW4064/DT compared with controls in these 
CD11b-depleted cohorts (Fig. 5B). DT treatment 
did not affect the expressions of FXR target genes 
induced by GW4064, indicating that CD11b+ cells 
were not involved in responding to FXR activation 
in liver (Fig. 5C). Thus, BMMs are dispensable in 
FXR-mediated liver protection from IRI.
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FXR aCtiVation inDuCes 
sHp to inHiBit tHe liVeR 
inFlammatoRy immune 
Response
As a well-known FXR target gene, SHP was 
demonstrated recently as a potent innate immune 
regulator.(27,28) We have shown in our own model 
that SHP induction is critical for the inhibition 
of the liver proinflammatory response and protec-
tion of liver from IRI in myeloid-glycogen synthase 
kinase 3 (Gsk3b)-deficient mice.(29) As shown above, 
Shp was induced in liver in vivo and KCs in vitro 
by GW4064 (Figs. 1 and 3). IR inhibited liver Shp 
expression, which was reversed at least partially by 
pharmacologic FXR activation (Fig. 3). KC depletion 
by CLs resulted in decreased liver Shp expression in 
both control and GW4064-treated hosts, indicating 
that KCs responded to FXR activation to up- regulate 
Shp expression (Fig. 4). To test the functional sig-
nificance of SHP induction in FXR-mediated liver 
protection, we administered SHP siRNA carried 
by mannose-conjugated polymers (selective deliv-
ery to phagocytes) in vivo before the onset of liver 
Fig. 4. KCs mediate the immune regulatory effect of FXR activation in liver IRI. Groups of WT B6 mice were treated with either blank 
or clodronate liposomes 48 hours before, followed by the treatment of either vehicle controls or GW4064 2 hours before the onset of liver 
ischemia. Liver injuries and inflammatory immune responses were evaluated at 6 hours after reperfusion. (A) Plots of average sALT levels, 
representative liver histologic analysis (HE staining, magnification ×100), and plots of average Suzuki’s scores in different experimental 
groups. (B,C) Plots of average target gene/HPRT expression ratios in different experimental groups. Liver inflammatory and FXR-
targeted gene expressions were determined by qRT-PCR. Representative results of at least two independent experiments; Data represent 
Mean ± SD, n = 3-6/group; *P < 0.05. Abbreviation: NS, not significant.
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ischemia.(30) Compared with control (scrambled [s]) 
siRNA, SHP-specific siRNA prohibited Shp up- 
regulation induced by GW4064 after IR, whereas 
other FXR target genes, such as Ostβ and Bsep, 
remained responsive to GW4064 treatment (Fig. 6A). 
Shp knockdown (KD) diminished inhibition of Cyp7a1 
expression by GW4064. Most importantly, FXR acti-
vation was no longer able to protect liver from IRI 
or inhibit the liver proinflammatory response in SHP 
KD hosts. Mice treated with SHP siRNA had signifi-
cantly higher levels of sALT, more severely damaged 
liver histologic architectures (Fig. 6B), and increased 
levels of TNF-α, IL-1β, and IL-6 but not IL-10 gene 
inductions in IR livers (Fig. 6C) compared with those 
treated with ssiRNA when both groups received the 
preoperational GW4064 treatment.
In vitro, SHP KD in KCs resulted in higher lev-
els of TNF-α, IL-1β, and IL-6 but a lower level 
of IL-10 gene inductions following LPS stimu-
lation (Fig. 7). Importantly, SHP KD diminished 
the immune regulatory effect of pharmacologic 
activation of FXR in KCs such that levels of TNF-α, 
IL-1β, IL-6, and IL-10 remained the same in 
GW4064-treated and vehicle-treated cells follow-
ing LPS stimulation. These results demonstrate 
that SHP induction in KCs is critical for the anti- 
inflammatory and liver-protective effects of phar-
macologic activation of FXR against IRI.
Discussion
Our study demonstrates that pharmacologic acti-
vation of FXR protects liver from IRI at both acute 
and recovery stages. Although FXR agonists have 
been shown to protect multiple organs from IRI in 
the heart, intestine, kidney, and liver models(16-19) 
and modulate liver inflammation in non-IRI models, 
cellular targets of FXR activation and immune regu-
latory mechanisms have not been well defined. Our 
results showed that the FXR-targeted gene SHP was 
critical for the therapeutic effect of FXR activation 
Fig. 5. CD11b+ BMMs are dispensable for FXR-mediated liver protection. CD11b-DTR mice were treated with either phosphate-
buffered saline (Ctl) or DT 48 hours before, followed by the treatment of either vehicle controls or GW4064 2 hours before the onset of 
liver ischemia, as described in Materials and Methods. Liver injuries and inflammatory immune responses were evaluated at 6 hours after 
reperfusion. (A) Plots of average sALT levels and Suzuki scores in different experimental groups. Representative HE staining (magnification 
×100) of IR livers. (B, C) Plots of average target gene/HPRT expression ratios in different experimental groups. Expressions of liver 
inflammatory and FXR-targeted genes were determined by qRT-PCR. Representative results of at least two independent experiments; 
Data represent Mean ± SD, n = 3-6/group; *P < 0.05. Abbreviation: h, hour.
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in liver IRI. Liver-resident KCs rather than infiltrat-
ing BMMs respond to FXR activation to up-regulate 
SHP, which suppresses proinflammatory gene expres-
sions downstream of TLRs.
Consistent with findings in a rat liver transplan-
tation model,(31) we showed that IR down-regulated 
FXR expressions and transcriptional activities in 
liver and KCs. We showed that KCs isolated from 
ischemic liver increase proinflammatory cytokine 
production but decrease anti-inflammatory IL-10 
production following TLR stimulation in vitro com-
pared with those from sham livers.(30) Because FXR 
regulates KC activation, its down-regulation by IR 
may potentially facilitate the KC proinflammatory 
response. In hepatocytes, it was shown that FXR could 
selectively inhibit nuclear factor kappa B (NF-κB) 
activation-initiated inflammatory gene expressions, 
including inducible nitric oxide synthase (iNOS) and 
 cyclooxygenase 2 (COX-2), even in the absence of its 
ligands.(32) FXR-deficient mice have been shown to 
develop much worse liver necrosis and more severe 
inflammation after treatment with LPS(32) or conca-
navalin A (ConA),(33) and FXR agonists reduce not 
only acute inflammatory hepatocellular damage(34) 
but also inflammatory cell infiltration and hepatic 
fibrosis/steatosis(35-37) in chronic liver disease mod-
els. Although liver MФs have been implicated as 
FXR-targeted cells in liver, evidence is derived from 
in vitro cell-culture experiments.(35) Our study identi-
fies KCs as the key mediator of the therapeutic effect 
of FXR activation in vivo by differential analysis of 
KCs versus BMMs both in vitro and in vivo. Our 
results show that KCs express much higher levels of 
FXR than BMMs. FXR activation decreases TNF-α 
Fig. 6. SHP is critical for FXR-mediated liver protection. Scrambled or SHP-specific siRNA was injected into different groups of B6 mice, 
followed by the administration of vehicle control or GW4064, as described in Materials and Methods. Liver IRI was evaluated at 6 hours 
after reperfusion. Expressions of FXR-target genes and inflammatory genes in IR livers were measured by qRT-PCR. (A) Plots of average 
ratios of target gene/HPRT expressions in different experimental groups. (B) Plots of average sALT levels and Suzuki’s scores in different 
experimental groups. Representative liver histologic images (HE staining, magnification ×100). (C) Plots of average target gene/HPRT 
rations in different experimental groups. Gene expressions were determined by qRT-PCR. Representative results of at least two independent 
experiments; Data represent Mean ± SD, n = 3-6/group; *P < 0.05. Abbreviations: h, hour; ssiRNA, scrambled small interfering RNA.
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and increases IL-10 gene expressions in KCs in vitro 
by inducing SHP expression. KC depletion results in 
diminished expressions of FXR target genes in liver 
and abrogates the protection of liver from IRI by 
the treatment of FXR agonist GW4064 in vivo. In 
contrast, there are no SHP inductions or alterations 
in inflammatory gene expressions in BMMs follow-
ing FXR activation in vitro. Depletion of BMMs 
in vivo did not affect the liver-protective effect by 
the agonist treatment. Although CLs and DT are not 
specific in targeting KCs and BMMs, respectively, 
in vivo, our regimen was a single-dose treatment 
before the onset of liver ischemia. Thus, CLs would 
mainly deplete tissue-resident MФs, including KCs, 
without affecting circulating monocytes (low phago-
cytic), whereas DT would deplete monocytes without 
affecting KCs (CD11blow/−) in the acute phase of liver 
IRI. In chronic liver disease models, FXR stimulation 
decreased or altered infiltrations of inflammatory 
monocytes.(35,37) In our study, GW4064 significantly 
inhibited KC chemokine production, for example, 
monocyte chemoattractant protein 1 (MCP1) and 
macrophage inflammatory protein 2 (MIP2), in vitro 
following TLR4 stimulation (data not shown), which 
may lead to decreases in liver infiltration of periph-
eral monocytes in vivo. Hepatocytes or natural killer 
T cells have been shown to respond to FXR activa-
tion, leading to protection from endotoxin- or ConA-
induced hepatitis, respectively.(32,33) Because FXR is 
expressed in various types of liver cells, cellular targets 
of FXR therapeutics in vivo may vary depending on 
the pathologic mechanism of liver diseases.
In hepatocytes, FXR has been shown to suppress 
NF-κB DNA binding(32) and up-regulate suppressor 
of cytokine signaling 3 (SOCS3).(34) In MФ cell lines, 
nuclear receptor corepressor 1 (NCoR1) mediates the 
Fig. 7. SHP is critical for FXR-mediated immune regulation in KCs. KCs were transfected with either scrambled or SHP-specific 
siRNA. Transfected cells were pretreated with either PBS or GW4064, followed by 3 hours of stimulation of LPS. Gene expressions were 
determined by qRT-PCR. Average ratios of target gene/HPRT ratios in different experimental groups were plotted. Representative results 
of at least two independent experiments; Data represent Mean ± SD, n = 3/group; *P < 0.05. Abbreviations: PBS, phosphate-buffered 
saline; SC, scrambled small interfering RNA.
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anti-inflammatory effects of FXR.(38) NCoR1 pre-
vents direct binding of NF-κB subunit to promoters 
of proinflammatory genes in unstimulated cells, which 
is stabilized by activated FXR. More recently, FXR 
was found to coprecipitate with NLR family pyrin 
domain containing 3 (NLRP3), caspase-1, and pos-
sibly apoptosis-associated speck-like protein (ASC) 
in MФs to prevent NLRP3 inflammasome assembly 
and activation.(39) Paradoxically, natural FXR ligand 
bile acids, alone or in synergy with LPS or adenos-
ine triphosphate, activated NLRP3 inflammasome by 
promoting calcium influx.(39) This indicates that FXR 
suppresses NLRP3 inflammasome possibly by their 
direct physical interactions but not by FXR ligand- 
induced transcriptional activities. Because GW4064 
does not inhibit NLRP3 inflammasome activation,(39) 
this particular mechanism may not be relevant to the 
effect of FXR activation in our model. Interestingly, 
bile acids have a G protein-coupled membrane recep-
tor, TGR5, which has been shown to not only repress 
NLRP3 inflammasome(40) but also inhibit NF-κB 
transcriptional activities by facilitating the interaction 
between inhibitor of κBα (IκBα) and β-arrestin2.(41) 
Although molecular and cellular details of the distinc-
tive effects of FXR and TGR5 on inflammasome acti-
vation in the absence or presence of bile acids remain 
to be fully elucidated, differential expressions of these 
receptors in different types of cells may be a key fac-
tor in determining their involvement in immune reg-
ulation. Our data show that KCs rather than BMMs 
express functional FXR. Therefore, pharmacologic 
activation of FXR selectively regulates KCs but not 
BMMs in their response to inflammatory stimulation. 
TGR5, on the other hand, is expressed in both types 
of MФs,(42,43) and pharmacologic activation of TGR5 
therefore regulates both of them in response to TLRs. 
One key difference in the immune regulatory mecha-
nisms between FXR and TGR5 activation in KCs is 
the induction of SHP, which turns out to be the criti-
cal mediator of the FXR therapeutic effect in liver IRI.
Our results reveal that SHP, as a direct FXR-
targeted gene, is crucial for the immune regulatory 
effect of FXR activation in KCs in liver IRI. SHP was 
identified recently as an endogenous negative regula-
tor in inflammatory signaling downstream of TLRs 
and NLRs.(27,28,44) It suppresses NF-κB activities 
by physically binding to either the NF-κBp65 sub-
unit at resting state and/or TNF receptor-associated 
factor 6 (TRAF6) following stimulation to inhibit 
its polyubiquitination and activation, leading to 
down-regulation of TNF-α and IL-6 transcrip-
tions.(28) SHP also interferes with the interaction 
between NLRP3 and ASC to intercept the assembly 
of the NLRP3 inflammasome complex, resulting in 
down-regulation of IL-1β and IL-18 production in 
NLRP3-activated MФs.(27) SHP could be translo-
cated to the mitochondria with the NLRP3–ASC 
complex after inflammasome activation and acts 
to regulate mitochondrial homeostasis through 
the recovery of mitochondrial reactive oxygen spe-
cies generation and damage.(28) Most recently, we 
have shown in the same liver IR model that Gsk3b 
promotes liver inflammatory immune activation 
through inhibition of adenosine monophosphate- 
activated protein kinase activation and SHP induc-
tion.(29) SHP has been implicated in other liver 
disease models. FXR-induced SHP in hepatic stel-
late cells has been shown to promote resolution of 
liver fibrosis by interacting with c-Jun to prevent 
activator protein 1 (AP-1) binding to inflamma-
tory genes.(45) SHP genetic deletion sensitizes mice 
to liver injuries triggered by bile duct ligation.(46) 
Interestingly, FXR and SHP double-KO mice are 
protected from hepatic steatosis due to their roles in 
lipid metabolism.(47)
In summary, we document by pharmacologic 
activation that FXR is a negative regulator of liver 
inflammatory immune response against IR. Its acti-
vation induces SHP up-regulation in KCs, leading to 
decreases of proinflammatory but increases of anti- 
inflammatory gene expression following TLR stimu-
lation and protection of liver from IRI.
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